Connect with us
Information

WORLD EDITION
Australia
North America
World

Investing News NetworkYour trusted source for investing success

WORLD EDITION
North America
Australia
World
My INN

Private Placements

Reports & Guides
- Market Outlook Reports
- Investing Guides

Precious Metals
Battery Metals
Base Metals
Energy
Critical Metals

Lead Market
Lead News
Lead Stocks

Acumen Pharmaceuticals Inc.

NASDAQ:ABOS:US

Featured Articles and Interviews

More Featured Articles and Inverviews

Press Releases

May 14, 2024

Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights

May 13, 2024

Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 08, 2024

Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference

More Press Releases

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what we believe to be a key underlying cause of Alzheimer's disease. The company's lead drug candidate, ACU193, is a subclass monoclonal antibody which selectively targets amyloid-beta oligomers.

Go Deeper

AI Powered

Senior woman doing exercises alongside closeup of DNA.

5 US Longevity and Anti-aging Stocks to Watch in 2025

Microscopic view of stem cells.

Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025

Interactive Chart

Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.